Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Patient-specific tumor neoantigen-specific T-cell receptors (NeoTCRs) are specialized proteins engineered to recognize unique mutations, or neoantigens, present only in an individual patient's tumor cells [1]. These neoantigens result from somatic mutations that create novel protein sequences not found in the normal human genome, providing a highly specific target for the immune system [2]. In clinical applications, NeoTCRs are typically used in adoptive cell transfer (ACT) therapies, where a patient's T-cells are genetically modified to express a TCR that has been identified and validated to bind a specific neoepitope presented by the patient's Major Histocompatibility Complex (MHC) [3]. Upon re-infusion, these engineered T-cells circulate and infiltrate tumor sites, where the NeoTCR binds to its cognate antigen, triggering T-cell activation, proliferation, and the release of cytotoxic molecules like granzymes and perforins to kill the cancer cells [5]. This personalized approach is designed to minimize "off-target" damage to healthy tissues, as the target antigens are absent outside the tumor [1]. However, challenges remain, including the complex process of neoantigen identification, the potential for tumor escape through HLA downregulation, and the risk of cytokine-related toxicities [5]. Current research focuses on optimizing the identification of high-affinity TCRs and improving the persistence of the engineered cells within the immunosuppressive tumor microenvironment [2].
NeoTCRs function by binding to specific neoepitopes (mutated peptides) presented by the patient's HLA molecules on the tumor cell surface, which triggers the formation of an immunological synapse, T-cell signaling via the CD3 complex, and subsequent release of cytotoxic effectors like perforin and granzymes to induce apoptosis in the target cell [1, 5].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Patient-specific tumor neoantigen-specific T-cell receptor (NeoTCR) (NeoTCR).